News & Events<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t![\"download](\"https:\/\/www.wockhardt.com\/wp-content\/themes\/wockhardt\/assets\/images\/Ellipse)
<\/a><\/p>July 9, 2023 Wockhardt charting a recovery riding on a promising new antibiotic<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>June 10, 2023 Engaging the pharmaceutical industry in joint efforts to tackle antimicrobial resistance<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>February 21, 2023 A game-changer: India\u2019s under-trial drug shows promise against hospital superbugs
<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>February 12, 2023 Under-trial antibiotic use saves minor thalassemia patient\u2019s life<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>November 13, 2022 Desi superbug antibiotic under trial saves Nepalese <\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>August 16, 2022 Wockhardt initiates phase-III clinical study of new antibiotic candidate
<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>March 16, 2022 National Institutes of Health (NIH), USA to conduct human Phase 1 trial of Wockhardt\u2019s novel once-a-day MDR Gram-negative antibiotic WCK 6777
<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>July 9, 2023 Wockhardt charting a recovery riding on a promising new antibiotic<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>June 10, 2023 Engaging the pharmaceutical industry in joint efforts to tackle antimicrobial resistance<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>February 21, 2023 A game-changer: India\u2019s under-trial drug shows promise against hospital superbugs
<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>February 12, 2023 Under-trial antibiotic use saves minor thalassemia patient\u2019s life<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>November 13, 2022 Desi superbug antibiotic under trial saves Nepalese <\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>August 16, 2022 Wockhardt initiates phase-III clinical study of new antibiotic candidate
<\/a><\/h3><\/div><\/div><\/li>
<\/a><\/p>March 16, 2022 National Institutes of Health (NIH), USA to conduct human Phase 1 trial of Wockhardt\u2019s novel once-a-day MDR Gram-negative antibiotic WCK 6777
<\/a><\/h3><\/div><\/div><\/li>